Conclusion & Future Perspective
Peyronie's disease involves the development of inelastic scar of the tunica albuginea of the penis, resulting in penile deformity and sexual dysfunction. New oral medications, targeted to underlying pathophysiology, are needed to effectively treat this disorder, in addition to the rigorous testing of current candidate agents. Intralesional injection therapies provide a viable and additional minimally invasive route for patients with PD. Surgical therapy is a valuable option to restore penile morphology and improve sexual function in selected patients. At this time, there are no prognostic tests available to predict progression of disease; serum or plaque proteomics may offer potential in the future for treatment planning and disease severity stratification. In the meantime, information on PD needs to be disseminated to both healthcare providers and patients, and male sexual health questions should become a standard aspect of periodic health evaluation.
Financial & competing interests disclosure
br/> Dr Shamloul is an Eli Lilly Canada Basic Science and Clinical Research Fellow 2010–2012. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Aging Health. 2011;7(1):65-78. © 2011 Future Medicine Ltd.
Cite this: Management of Peyronie's Disease in the Aging Male - Medscape - Feb 01, 2011.